Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 689 for cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    Rochester, MN

  2. 3D Ultrasound Imaging for Breast Cancer Diagnosis

    Rochester, MN

  3. Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

    Rochester, MN

  4. Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

    Jacksonville, FL, Rochester, MN

  5. Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

    Jacksonville, FL, Rochester, MN

  6. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. (Neo)Adjuvant IDE196 (Darovasertib) In Patients With Localized Ocular Melanoma

    Rochester, MN

  8. A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

    Rochester, MN

  9. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    Rochester, MN

  10. Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer